Home > News & Topics
- 2025.4.11
- Termination of License Agreement between TMRC and Syros Pharmaceuticals .
- 2024.11.13
- Syros Pharmaceuticals Inc., announced Topline Data from SELECT-MDS-1 Phase 3 Trial of Tamibarotene in Higher-Risk Myelodysplastic Syndrome with RARA Gene Overexpression.
- 2024.08.14
- Syros Pharmaceuticals Inc., has announced that it will no longer be enrolling new patients in its clinical trial for AML.
- 2024.04.10
- FDA has granted Fast Track Designation to Tamibarotene for the treatment of Newly Diagnosed Unfit AML.
- 2023.01.27
- FDA has granted Fast Track Designation to Tamibarotene for the treatment of higher risk MDS.
- 2022.08.04
- EMA committee issued Positive Opinion to TM-411 for MDS on Orphan Drug Designation.
- 2022.07.11
- Approval of use patent for TM-411 as a cancer stem cell proliferation inhibitor by European Patent Office.
- 2022.04.13
- Research group led by researchers at Dept. of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, published in"Oncogene" on the effect of TM-411 to ameliorate the susceptibility of chemotherapy to pancreatic cancer.
- 2022.02.03
- FDA designated TM-411 for MDS as an Orphan Drug.
- 2021.09.10
- First patient enrolled in Phase II clinical trial of TM-411 in triplet combination with venetoclax and azacitidine for AML in US.
- 2021.05.10
- First patient enrolled in phaseⅢ clinical trial of TM-411 in combination with azacitidine for higher-risk MDS in US.
- 2021.01.12
- Reached an agreement with Syros Pharmaceuticals Inc., to be granted for the Biomarker License.
- 2021.01.12
- Reached agreement with Syros Pharmaceuticals Inc., to add the Southern America & Oceania regions in the territory in the license agreement dated Sept. 2015.